Report Tools

OTC Pharmaceuticals in the Netherlands

Published: August 2013 · Publisher: MarketLine
OTC Pharmaceuticals in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017).
Report Type Industry Profiles
Language English
Format Electronic (PDF)
Pages39
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-7402
Price € 259,00
Options
  • Description
  • Companies Mentioned
  • Table of Contents
  • Ask a Question
Introduction

OTC Pharmaceuticals in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Netherlands otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2012 annual average exchange rates.

*The Dutch OTC pharmaceuticals market had total revenues of $1,090.3m in 2012, representing a compound annual growth rate (CAGR) of 2.4% between 2008 and 2012.

*The vitamins and minerals segment was the market's most lucrative in 2012, with total revenues of $236.6m, equivalent to 21.7% of the market's overall value.

*The performance of the market is forecast to follow the similar pattern with an anticipated CARC of 2.4% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $1,227.4m by the end of 2017.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in the Netherlands

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in the Netherlands

Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands otc pharmaceuticals market with five year forecasts by both value and volume

Macroeconomic indicators provide insight into general trends within the Netherlands economy

Key Questions Answered

What was the size of the Netherlands otc pharmaceuticals market by value in 2012?

What will be the size of the Netherlands otc pharmaceuticals market in 2017?

What factors are affecting the strength of competition in the Netherlands otc pharmaceuticals market?

How has the market performed over the last five years?

Who are the top competitiors in the Netherlands's otc pharmaceuticals market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Bayer AG, Boehringer Ingelheim GmbH, Johnson & Johnson and Novartis AG
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Geography segmentation 10
Market share 11
Market distribution 12
Market Outlook 13
Market value forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Bayer AG 20
Boehringer Ingelheim GmbH 24
Johnson & Johnson 28
Novartis AG 31
Macroeconomic Indicators 35
Country Data 35
Appendix 37
Methodology 37
Industry associations 38
Related research 38

LIST OF TABLES
Table 1: Netherlands OTC pharmaceuticals market value: $ million, 2008–12 8
Table 2: Netherlands OTC pharmaceuticals market category segmentation: $ million, 2012 9
Table 3: Netherlands OTC pharmaceuticals market geography segmentation: $ million, 2012 10
Table 4: Netherlands OTC pharmaceuticals market share: % share, by value, 2012 11
Table 5: Netherlands OTC pharmaceuticals market distribution: % share, by value, 2012 12
Table 6: Netherlands OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Table 7: Bayer AG: key facts 20
Table 8: Bayer AG: key financials ($) 21
Table 9: Bayer AG: key financials (€) 21
Table 10: Bayer AG: key financial ratios 22
Table 11: Boehringer Ingelheim GmbH: key facts 24
Table 12: Boehringer Ingelheim GmbH: key financials ($) 25
Table 13: Boehringer Ingelheim GmbH: key financials (€) 25
Table 14: Boehringer Ingelheim GmbH: key financial ratios 26
Table 15: Johnson & Johnson: key facts 28
Table 16: Johnson & Johnson: key financials ($) 29
Table 17: Johnson & Johnson: key financial ratios 29
Table 18: Novartis AG: key facts 31
Table 19: Novartis AG: key financials ($) 32
Table 20: Novartis AG: key financial ratios 33
Table 21: Netherlands size of population (million), 2008–12 35
Table 22: Netherlands gdp (constant 2000 prices, $ billion), 2008–12 35
Table 23: Netherlands gdp (current prices, $ billion), 2008–12 35
Table 24: Netherlands inflation, 2008–12 36
Table 25: Netherlands consumer price index (absolute), 2008–12 36
Table 26: Netherlands exchange rate, 2008–12 36

LIST OF FIGURES
Figure 1: Netherlands OTC pharmaceuticals market value: $ million, 2008–12 8
Figure 2: Netherlands OTC pharmaceuticals market category segmentation: % share, by value, 2012 9
Figure 3: Netherlands OTC pharmaceuticals market geography segmentation: % share, by value, 2012 10
Figure 4: Netherlands OTC pharmaceuticals market share: % share, by value, 2012 11
Figure 5: Netherlands OTC pharmaceuticals market distribution: % share, by value, 2012 12
Figure 6: Netherlands OTC pharmaceuticals market value forecast: $ million, 2012–17 13
Figure 7: Forces driving competition in the OTC pharmaceuticals market in the Netherlands, 2012 14
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in the Netherlands, 2012 15
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in the Netherlands, 2012 16
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in the Netherlands, 2012 17
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in the Netherlands, 2012 18
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in the Netherlands, 2012 19
Figure 13: Bayer AG: revenues & profitability 22
Figure 14: Bayer AG: assets & liabilities 23
Figure 15: Boehringer Ingelheim GmbH: revenues & profitability 26
Figure 16: Boehringer Ingelheim GmbH: assets & liabilities 27
Figure 17: Johnson & Johnson: revenues & profitability 29
Figure 18: Johnson & Johnson: assets & liabilities 30
Figure 19: Novartis AG: revenues & profitability 33
Figure 20: Novartis AG: assets & liabilities 34
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.